12567 Hybrid Closed-loop Insulin Pumps' Role In CFRD Management: A Retrospective Case Series Analysis

Abstract Disclosure: I. Yaseen: None. D. Slattery: None. Cystic fibrosis-related diabetes (CFRD) significantly burdens individuals with cystic fibrosis (CF), notably influencing their health longevity and quality of life. This case series retrospectively examines the effects of hybrid closed-loop (HCL) insulin pump therapy on CFRD management strategies. We reviewed clinical data from 8 CFRD patients between the ages of 19-37 who were transitioned to HCL insulin pump therapy over a three-month interval. Seven patients managed their condition with the Control IQ system, combining the Tandem t:slim insulin pump with the Dexcom G6 CGM sensor . One patient employed the Medtronic MiniMed™ 780G system, coupled with a Guardian 4 sensor. Our analytical survey spanned across multiple health metrics pre- and post-HCL therapy initiation, including hemoglobin A1c (HbA1c) levels, percentage of time in the target glucose range, hypoglycemic event frequency, FEV1 scores from pulmonary function tests, body mass index (BMI), and CF-specific quality of life (CFQ-R) scores. The findings highlighted a considerable decline in HbA1c, with averages falling from 73.71 mmol/mol at baseline to 56.6 mmol/mol in five patients at the conclusion of the three-month treatment follow-up. Three patients are pending another HbA1c evaluation despite routine virtual clinical follow-ups. Hypoglycemia was uncommon, consistently <1% both pre- and post-intervention. Within the available data, time in target glucose range impressively increased from 39.10% before to 63.8% after pump application. For three patients, pulmonary function test results indicated either maintenance or marginal improvement; assessments for the other participants are still upcoming. An average BMI increase of 1.5 kg/m² signals positive implications for patients' nutritional health. While comprehensive CFQ-R outcome assessments are ongoing, preliminary indications suggest progress. Concluding, this case series highlights the advantageous role of HCL insulin pumps in enhancing glycemic control and curbing glucose fluctuations in CFRD without increasing hypoglycemia risks. The uplift in nutritional status with no adverse impact on pulmonary function endorses the HCL approach as effective in CFRD treatment protocols. These promising short-term outcomes advocate for extended research and analysis, with a focus on substantiating long-term clinical benefits. Presentation: 6/1/2024